scorecardresearch
Add as a preferred source on Google
Friday, December 19, 2025
TopicHydroxychloroquine

Topic: hydroxychloroquine

India sold over 22 crore HCQ tablets in last 3 months against 24 crore in all of 2019

The Rs 3-tablet, which earlier emerged as a front-runner for Covid treatment, also recorded a massive jump of 700 per cent in exports between March & May.  

Trump’s dash to Patanjali for Covid-19 ‘cure’, and Bollywood’s deadly nepotism

The best cartoons of the day, chosen by the editors at ThePrint.

US FDA revokes authorisation given for emergency use of HCQ to treat Covid

Chloroquine and hydroxychloroquine ‘are unlikely to be effective in treating Covid-19’, the US Food and Drug Administration said.

Health ministry revises stance on HCQ for Covid treatment, allows remdesivir for emergency use

In a new set of protocols, the ministry backtracked from its earlier stance and recommended HCQ in the early course of the disease but not in severe cases.

Why the HCQ-Trump-Lancet saga shouldn’t erode public trust in science

Science in the long haul is self-correcting, it never finds absolute truth, and it sometimes trips, but it can right itself and move on.

The Lancet, world’s most credible medical journal whose trust has been hit by HCQ scandal

‘The Lancet’ retracted a key study that linked anti-malarial drug HCQ to increased risk of death and irregularity in heart rhythms in coronavirus patients.

‘Star’ cardiologist Mehra & data doctor Desai — story of Indian experts behind HCQ scandal

Mandeep R. Mehra, who graduated from a medical college in Maharashtra, is now a professor at Harvard, while Sapan S. Desai founded the data analytics firm Surgisphere.

The HCQ study mess: How 3 Indian researchers put reputation of Lancet, NEJM at stake

In episode 489 of #CutTheClutter, Shekhar Gupta discusses the controversial studies that were retracted after scientists around the world raised questions on its data accuracy.

HCQ doesn’t reduce risk of death among hospitalised Covid patients, says Oxford study

About 26% of patients in the trial getting the drug died, compared with about 24% receiving standard care, according to the University of Oxford.

Surgisphere, the Indian-American founded tiny data firm at the centre of HCQ-Lancet storm

Sapan Desai, a 41-year-old surgeon, is the founder of the analytics company that prompted the retraction of two scientific articles, including one that spurred WHO to pause its drug trial.

On Camera

What the key political events of 2025 tell us about Narendra Modi and India’s future

From Operation Sindoor to India-US tensions to the EC controversies, a clear understanding has emerged about where the politics is headed now.

Antitrust watchdog Competition Commission to probe IndiGo flight disruptions

While the commission didn’t mention provisions under which IndiGo's market domination would be examined, Competition Act 2002 prohibits abuse of dominant position by any enterprise.

Israel has ‘realised who its real friend is’, eyes defence expansion in India amid arms curbs by others

It is argued that India-Israel ties are moving from buyer–seller dynamic to one focused on joint development & manufacturing partnership, a shift 'more durable' than traditional arms sales.

India’s top airline just handed sarkar the keys. That’s IndiGo’s real ‘crime’

Don’t blame misfortune. This is colossal incompetence and insensitivity. So bad, heads would have rolled even in the old PSU-era Indian Airlines and Air India.